Table 8. Rates of systemic adverse effects of RCTs evaluating ranibizumab for indirect comparison and dose-relationship evaluation.

Study	Death (any cause) (%)			Myocardial infarction (%)			Cerebrovascular accident (%)			Nonocular haemorrhage (%)			Infections (%)
	0.3 mg	0.5 mg	PDT	0.3 mg	0.5 mg	PDT	0.3 mg	0.5 mg	PDT	0.3 mg	0.5 mg	PDT	0.3 mg	0.5 mg	PDT
ANCHOR 2009 [21]	3.7	2.1	3.5	0.7	3.6	1.4	2.2	0.0	1.4	2.9	2.1	0.7	nr	nr	nr
	0.3 mg	0.5 mg	Sham	0.3 mg	0.5 mg	Sham	0.3 mg	0.5 mg	Sham	0.3 mg	0.5 mg	Sham	0.3 mg	0.5 mg	Sham
MARINA 2006 [22]	2.1	2.5	2.5	2.5	1.3	1.7	1.3	2.5	0.8	1.3	2.1	0.8	nr	nr	nr
PIER 2010 [23]	3.4	0.0	1.6	0.0	0.0	1.6	0.0	0.0	0.0	6.8	9.8	4.8	nr	nr	nr
	0.3 mg	0.5 mg		0.3 mg	0.5 mg		0.3 mg	0.5 mg		0.3 mg	0.5 mg		0.3 mg	0.5 mg
SAILOR 2009 [24]	1.7	2.4		1.2	1.2		0.7	1.2		0.9	1.5		nr	nr
	0.3 mg*	0.5 mg*	0.3 mg#	0.3 mg*	0.5 mg*	0.3 mg#	0.3 mg*	0.5 mg*	0.3 mg#	0.3 mg*	0.5 mg*	0.3 mg#	0.3 mg*	0.5 mg*	0.3 mg#
EXCITE 2011 [25]	0.0	1.6	0.9	0.8	0.0	0.9	0.8	0.0	0.9	0.0	3.4	0.9	2.5	4.2	3.5

Nr: Not reported.

^*Quarterly.

^#Monthly.